| ID Source | ID |
|---|---|
| PubMed CID | 2327953 |
| CHEMBL ID | 1423690 |
| CHEBI ID | 93241 |
| SCHEMBL ID | 17515282 |
| Synonym |
|---|
| smr000060796 |
| MLS000057572 , |
| MLS-0022297.0001 |
| MLS000879866 |
| MLS002460506 |
| 2-(4-methyl-3-piperidin-1-ylsulfonylphenyl)-1,2-benzothiazol-3-one |
| HMS2219L10 |
| HMS3357H03 |
| 2-(4-methyl-3-piperidin-1-ylsulfonyl-phenyl)-1,2-benzothiazol-3-one |
| bdbm34340 |
| 2-(4-methyl-3-piperidinosulfonyl-phenyl)-1,2-benzothiazol-3-one |
| cid_2327953 |
| 2-[4-methyl-3-(1-piperidinylsulfonyl)phenyl]-1,2-benzothiazol-3-one |
| CHEMBL1423690 |
| SCHEMBL17515282 |
| CHEBI:93241 |
| Z56798582 |
| 2-[4-methyl-3-(1-piperidylsulfonyl)phenyl]-1,2-benzothiazol-3-one |
| 716376-21-5 |
| Q27164958 |
| AKOS034456059 |
| 2-[4-methyl-3-(piperidine-1-sulfonyl)phenyl]-2,3-dihydro-1,2-benzothiazol-3-one |
| CS-0094443 |
| EN300-252104 |
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 2.2387 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 9.9763 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 0.5553 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 0.5553 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 7.9433 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 11.2202 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 12.5893 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 17.4302 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 0.5012 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 1.5849 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| GLS protein | Homo sapiens (human) | Potency | 6.3096 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 2.6101 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 23.7359 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
| Smad3 | Homo sapiens (human) | Potency | 11.2202 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 2.2387 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 3.9811 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 3.1623 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 14.1254 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 5.6234 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| IDH1 | Homo sapiens (human) | Potency | 5.1735 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 0.8913 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 3.1623 | 1.0000 | 12.2326 | 31.6228 | AID1452 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 1.0000 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 19.9526 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 3.5481 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 0.3548 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 0.8437 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 56.2341 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 22.3872 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| geminin | Homo sapiens (human) | Potency | 19.7347 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Vpr | Human immunodeficiency virus 1 | Potency | 15.8489 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 2.2387 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 0.1000 | 0.0200 | 10.7869 | 31.6228 | AID912 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 31.6228 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 0.6310 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 10.0000 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 0.6310 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 14.1254 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 8.7389 | 0.0601 | 10.7453 | 37.9330 | AID485367; AID504636; AID504637 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| MPI protein | Homo sapiens (human) | IC50 (µMol) | 34.3533 | 0.1900 | 13.8256 | 50.1000 | AID1209; AID1220; AID1535 |
| M18 aspartyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 (µMol) | 4.2840 | 0.3851 | 13.0782 | 100.0000 | AID2195 |
| neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 (µMol) | 1.5200 | 0.3900 | 6.5441 | 29.1200 | AID1275 |
| phosphomannomutase 2 | Homo sapiens (human) | IC50 (µMol) | 14.6000 | 0.6720 | 34.7838 | 97.3000 | AID1655 |
| alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.1250 | 16.2603 | 74.8000 | AID1056 |
| phosphoethanolamine/phosphocholine phosphatase isoform 1 | Homo sapiens (human) | IC50 (µMol) | 1.8400 | 0.1110 | 0.5769 | 0.9410 | AID1666 |
| eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | IC50 (µMol) | 1.9255 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| insulin-degrading enzyme isoform 1 | Homo sapiens (human) | IC50 (µMol) | 4.0540 | 2.1020 | 3.0092 | 4.0540 | AID463220 |
| eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | IC50 (µMol) | 1.9255 | 1.1500 | 12.6200 | 25.6529 | AID855 |
| Phosphomannomutase 2 | Homo sapiens (human) | IC50 (µMol) | 11.0000 | 5.2000 | 5.2000 | 5.2000 | AID1187643 |
| Mannose-6-phosphate isomerase | Homo sapiens (human) | IC50 (µMol) | 3.1000 | 0.7100 | 3.3175 | 6.4000 | AID1187642 |
| Phosphoethanolamine/phosphocholine phosphatase | Homo sapiens (human) | IC50 (µMol) | 1.8000 | 0.5000 | 2.1343 | 5.2000 | AID1187641 |
| large T antigen | Betapolyomavirus macacae | IC50 (µMol) | 26.0700 | 0.1600 | 24.9724 | 100.0000 | AID1903 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RGS7, partial | Homo sapiens (human) | EC50 (µMol) | 0.1400 | 0.1400 | 2.1300 | 4.7800 | AID1871 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | EC50 (µMol) | 30.0000 | 0.1350 | 3.3506 | 10.0690 | AID1872 |
| regulator of G-protein signaling 19 | Homo sapiens (human) | EC50 (µMol) | 0.6100 | 0.1150 | 3.1756 | 14.1300 | AID1884 |
| regulator of G-protein signaling 16 | Homo sapiens (human) | EC50 (µMol) | 2.0000 | 0.0530 | 3.6258 | 16.0000 | AID1888 |
| large T antigen | Betapolyomavirus macacae | EC50 (µMol) | 14.7400 | 0.1000 | 35.4896 | 50.0000 | AID2102 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1187643 | Inhibition of PMM2 (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. |
| AID1187641 | Inhibition of PHOSPHO1 phosphoethanolamine activity (unknown origin) assessed as amount of inorganic phosphate release after 30 mins | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. |
| AID1187642 | Inhibition of phosphomannose isomerase (unknown origin) | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||